Topic: ADHD

While Shire’s shareholders Wednesday celebrated a possible Takeda bid, the Japanese drugmaker’s investors ran for the exits.

Shire has a penchant for making headlines at the J.P. Morgan Healthcare Conference, and it did so again early Monday.

Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.

Shire's neuroscience unit, anchored by drugs to treat ADHD, may be on the block.

Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.

There’s a new FDA-approved ADHD medication on the scene, and it’s one maker Neos Therapeutics thinks will put it in prime market position.

Generics of Johnson & Johnson’s ADHD pill Concerta are hitting hard times due to an FDA crackdown on their bioequivalence. The agency said six months ago that generics makers Lannett and Mallinckrodt had that much time to confirm their extended-release technology matched that of J&J’s.

Plenty of drugmakers, including Shire and J&J, market ADHD drugs for children. But those drugs may not help kids do their homework or get better grades, a new study shows.

Highland Therapeutics, a Toronto-based company with delayed-release technology for ADHD treatment, is launching a Phase II study of its drug HLD100 designed for nighttime dosing of ADHD patients to improve their functioning when they wake.